Krebs Linda J
Center for Molecular Medicine, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030-3101, USA.
Curr Opin Investig Drugs. 2004 Oct;5(10):1080-5.
The calcium-sensing receptor (CaSR) is a key regulator of parathyroid hormone (PTH) secretion and parathyroid proliferation. This review discusses the role of the CaSR in hyperparathyroidism (HPT), and the exploitation of the CaSR as a therapeutic target for the treatment of HPT. Calcimimetics act as CaSR agonists or allosteric activators and thereby potentiate the effects of extracellular Ca2+ on parathyroid cell function. Results from clinical trials using calcimimetics to treat primary and secondary HPT, as well as primary HPT from parathyroid carcinoma, suggest that calcimimetic compounds could provide an effective alternative or additional therapeutic approach for various forms of HPT.
钙敏感受体（CaSR）是甲状旁腺激素（PTH）分泌和甲状旁腺增殖的关键调节因子。本综述讨论了CaSR在甲状旁腺功能亢进症（HPT）中的作用，以及将CaSR作为治疗HPT的治疗靶点的应用。拟钙剂作为CaSR激动剂或变构激活剂，从而增强细胞外Ca2+对甲状旁腺细胞功能的影响。使用拟钙剂治疗原发性和继发性HPT以及甲状旁腺癌引起的原发性HPT的临床试验结果表明，拟钙剂化合物可为各种形式的HPT提供一种有效的替代或额外治疗方法。
